REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,773.50
Bid: 1,772.00
Ask: 1,772.50
Change: 12.50 (0.71%)
Spread: 0.50 (0.028%)
Open: 1,770.00
High: 1,776.00
Low: 1,766.00
Prev. Close: 1,761.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Italian shares jump on Draghi hope; GSK weighs on FTSE 100

Wed, 03rd Feb 2021 09:18

* Milan stocks rise on hopes of Draghi becoming next PM

* Daimler jumps on plan to spin-off truck business

* GSK slides; warns of bigger than expected fall in 2021
earnings
(Updates to close)

By Shreyashi Sanyal and Susan Mathew

Feb 3 (Reuters) - Italian shares posted their best session
in four weeks on Wednesday after former European Central Bank
chief Mario Draghi accepted the task of forming a new
government, while a surge in German carmaker Daimler lifted an
index of broader European shares.

Milan's FTSE MIB index closed up 2.1%, while
Italy's 10-year bond yield tumbled.

Draghi said he was confident of securing sufficient backing
in parliament after President Sergio Mattarella sought his help
after hearing that efforts to salvage the collapsed coalition of
Prime Minister Giuseppe Conte had failed.

"It may not all be plain sailing and some uncertainties and
negotiations remain. But... markets like the news of well-known
central bankers at the helm of government," said Maria Paola
Toschi, global market strategist at J.P. Morgan Asset
Management.

"For the economy, avoiding lengthy further attempts to form
a government should mean that critical near-term issues can be
addressed."

Italy has been hit by the COVID-19 pandemic and economic
crises against the backdrop of political uncertainty battering
the country.

On the pan-European STOXX 600 index Daimler
was the top boost after unveiling plans to spin-off
its trucks business. It rose 8.9% while the broader index gained
0.3%.

Germany's DAX rose 0.7% to hit its highest in two
weeks.

London's blue-chip index slipped 0.1% as
GlaxoSmithKline slid 6.3% after it warned of a bigger
than expected fall in 2021 earnings as the COVID-19 pandemic
continues to disrupt other healthcare treatments.

But upbeat earnings from other companies helped push gains
on the pan-region index to a third straight day, with Novo
Nordisk, Siemens AG, Publicis Groupe SA
all rising after reporting results.

Drugmaker Argenx was the top gainer after it
raised $1 billion in capital increase.

Also keeping sentiment buoyed was hopes of U.S. stimulus
after the Senate took steps to allow Democrats to pass President
Joe Biden's proposed $1.9 trillion COVID-19 aid bill without
Republican support.

European stocks have been steadily rising along with other
major markets after losing more than 3% last week on concerns
around the slow roll-out of COVID-19 vaccines in the euro zone.

A pause in a social media driven rally that drove up prices
of silver as well as certain stocks including GameStop Corp
has helped calm worries about potential losses incurred
by certain hedge funds causing disruption to markets as a whole.
(Reporting by Shreyashi Sanyal in Bengaluru; Editing by Shounak
Dasgupta, Kirsten Donovan)

More News
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.